Related Experiment Video
Updated: Feb 16, 2026

Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
Published on: March 10, 2012
Use of Continuous Glucose Monitoring for Detecting and Understanding Early Dysglycemia in Cystic Fibrosis
Holly Cooper1, Christine L Chan2
1Stanford University School of Medicine, Palo Alto, CA, USA.
Insights
Cystic fibrosis-related diabetes (CFRD) is common in adults with cystic fibrosis (CF). Continuous glucose monitoring (CGM) shows promise for detecting early glucose issues in people with CF (pwCF) before CFRD develops.
Area of Science:
- Endocrinology
- Pulmonology
- Metabolic disorders
Background:
- Cystic fibrosis-related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis (CF).
- CFRD is linked to worse lung function, nutrition, and survival in people with CF (pwCF).
- Prediabetes and hyperglycemia in pwCF precede CFRD diagnosis and are associated with adverse health outcomes.
Purpose of the Study:
- To review and summarize current literature on continuous glucose monitoring (CGM) in the prediabetic state of pwCF.
- To highlight research gaps and needs regarding CGM use for early dysglycemia detection in CF.
Main Methods:
- Literature review of studies utilizing CGM in pwCF with prediabetes.
- Analysis of CGM data for insights into CFRD pathophysiology and early dysglycemia detection.
- Synthesis of current evidence on CGM application in CF prediabetes management.
Main Results:
- CGM is increasingly used in research and clinical settings for CFRD insights.
- Early glucose abnormalities, including prediabetes, are detectable years before CFRD diagnosis.
- The use of CGM for early dysglycemia detection in pwCF is growing.
Conclusions:
- CGM offers valuable insights into glucose metabolism in pwCF.
- Further research is needed to establish management guidelines for early glucose abnormalities detected by CGM in pwCF.
- The rising prevalence of CFRD due to increased longevity necessitates improved early detection and management strategies.
Abstract:
Cystic fibrosis-related diabetes (CFRD) is a common extrapulmonary manifestation of cystic fibrosis (CF) affecting up to 50% of adults. Cystic fibrosis-related diabetes is associated with poorer lung function, lower nutrition, and increased mortality. Abnormal blood glucoses, especially post-prandial hyperglycemia, can precede a diagnosis of CFRD by many years, and even the prediabetic state has been associated with poorer health outcomes in people with CF (pwCF). With the advent of cystic fibrosis transconductance regulator (CFTR) modulator therapies, the clinical landscape of CF is changing. With increasing longevity, the prevalence of CFRD is anticipated to rise. Continuous glucose monitoring (CGM) technology has been applied in research and clinical settings for insights into CFRD pathophysiology, and its use for early dysglycemia detection in the CF population is increasing. However, guidance around management of these early glucose abnormalities is limited. This article aims to review and summarize the current literature on use of CGM in the prediabetic state in pwCF and to highlight ongoing areas of research need.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Understanding the Self
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Understanding Self-Concept
Understanding Deception

